Helix BioPharma Corp. (TSE:HBP – Get Rating)’s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.21 and traded as high as C$0.22. Helix BioPharma shares last traded at C$0.21, with a volume of 23,219 shares trading hands.
Helix BioPharma Trading Down 10.9 %
The company has a 50 day moving average price of C$0.21 and a 200 day moving average price of C$0.21. The firm has a market cap of C$41.00 million and a price-to-earnings ratio of -3.66. The company has a debt-to-equity ratio of 773.67, a quick ratio of 1.04 and a current ratio of 1.08.
Helix BioPharma (TSE:HBP – Get Rating) last posted its earnings results on Wednesday, December 14th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. On average, research analysts expect that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.
Helix BioPharma Company Profile
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.